CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Dear Editor,Chimeric antigen receptor (CAR) T cell therapy is a promising approach to treat cancer,such as B-cell malignancy ”1”.However,the current standard treatment requires autologous adoptive cell transfer,which is expensive and time-consuming.For newborn and elder patients,it is often difficult to obtain enough T cells with good quality to generate patient-specific CAR-T cells.
27
This work was supported by the National Natural Science Foundation of China 31471215,the Strategic Priority Research Program of the Chinese Academy of Sciences XDA01010409,and the State 863 project 2015AA020307.HW is supported by the ”Young Thousand Talent Project”.
2017-02-27(万方平台首次上网日期,不代表论文的发表时间)
154-157